1. Search Result
Search Result
Results for "

heart failure patients

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10965

    KW-3902

    Adenosine Receptor Neurological Disease
    Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
    Rolofylline
  • HY-14252A
    Milrinone lactate
    30+ Cited Publications

    Win 47203 lactate

    Phosphodiesterase (PDE) Cardiovascular Disease
    Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock .
    Milrinone lactate
  • HY-78847

    Drug Metabolite Cardiovascular Disease
    2R,4S-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    2R,4S-Sacubitril
  • HY-78846

    Drug Metabolite Cardiovascular Disease
    2R,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    2R,4R-Sacubitril
  • HY-Z0081

    Drug Metabolite Cardiovascular Disease
    2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    2S,4R-Sacubitril
  • HY-103214A

    Adrenergic Receptor Cardiovascular Disease
    Bucindolol hydrochloride is a β-adrenergic receptor antagonist with activity in preventing new-onset atrial fibrillation. Bucindolol hydrochloride can reduce heart rate and the occurrence of bradycardia in patients with heart failure and atrial fibrillation .
    Bucindolol hydrochloride
  • HY-Z0075

    Drug Metabolite Cardiovascular Disease
    (Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    (Z)2S,4R-Sacubitril
  • HY-78847R

    Drug Metabolite Reference Standards Cardiovascular Disease
    2R,4S-Sacubitril (Standard) is the analytical standard of 2R,4S-Sacubitril. This product is intended for research and analytical applications. 2R,4S-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    2R,4S-Sacubitril (Standard)
  • HY-Z0075R

    Drug Metabolite Reference Standards Cardiovascular Disease
    (Z)2S,4R-Sacubitril (Standard) is the analytical standard of (Z)2S,4R-Sacubitril. This product is intended for research and analytical applications. (Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    (Z)2S,4R-Sacubitril (Standard)
  • HY-10965R

    KW-3902 (Standard)

    Adenosine Receptor Reference Standards Neurological Disease
    Rolofylline (Standard) is the analytical standard of Rolofylline. This product is intended for research and analytical applications. Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
    Rolofylline (Standard)
  • HY-124470

    Others Cardiovascular Disease
    Amisometradine is an orally active aminouracil diuretic with a diuretic potency approximately 40% that of Mersalyl (HY-108868) (when administered intramuscularly). Amisometradine exerts its effects by promoting the excretion of sodium, chloride and a small amount of potassium, exhibits significant therapeutic effects in heart failure models, and has good tolerance with long-term administration. Compared with drugs of the same class, Amisometradine causes fewer gastrointestinal reactions; its minor side effects mainly include nausea, vomiting, diarrhea, tinnitus and deafness, and are usually not accompanied by proteinuria or abnormalities in blood and urine indicators. Amisometradine is an important tool for the study of heart failure and related diuretic mechanisms .
    Amisometradine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: